Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/301% below fair value
$9.61−0.62 (-6.06%)
Close on Nov 13, 2026Market cap $647.14MP/E –Yield –
Ginkgo Bioworks ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Ginkgo Bioworks's ebitda for the twelve months ending Sep 30, 2026 was -$214.95M. For fiscal 2025 it was -$256.29M. The highest annual figure on record is -$60.84M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$256.29M | – |
| FY2024 | Dec 31, 2024 | -$496.74M | – |
| FY2023 | Dec 31, 2023 | -$793.90M | – |
| FY2022 | Dec 31, 2022 | -$2.17B | – |
| FY2021 | Dec 31, 2021 | -$1.80B | – |
| FY2020 | Dec 31, 2020 | -$123.16M | – |
| FY2019 | Dec 31, 2019 | -$60.84M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$31.60M | – |
| Q2 FY2026 | Jun 30, 2026 | -$46.23M | – |
| Q1 FY2026 | Mar 31, 2026 | -$58.58M | – |
| Q4 FY2025 | Dec 31, 2025 | -$78.54M | – |
| Q3 FY2025 | Sep 30, 2025 | -$68.68M | – |
| Q2 FY2025 | Jun 30, 2025 | -$42.91M | – |
| Q1 FY2025 | Mar 31, 2025 | -$66.15M | – |
| Q4 FY2024 | Dec 31, 2024 | -$87.95M | – |
| Q3 FY2024 | Sep 30, 2024 | -$38.04M | – |
| Q2 FY2024 | Jun 30, 2024 | -$205.62M | – |
| Q1 FY2024 | Mar 31, 2024 | -$165.13M | – |
| Q4 FY2023 | Dec 31, 2023 | -$165.28M | – |
| Q3 FY2023 | Sep 30, 2023 | -$265.33M | – |
| Q2 FY2023 | Jun 30, 2023 | -$166.50M | – |
| Q1 FY2023 | Mar 31, 2023 | -$196.79M | – |
| Q4 FY2022 | Dec 31, 2022 | -$215.20M | – |
| Q3 FY2022 | Sep 30, 2022 | -$646.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$638.75M | – |
| Q1 FY2022 | Mar 31, 2022 | -$666.43M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.68B | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.39M | – |
| Q2 FY2021 | Jun 30, 2021 | -$52.78M | – |
| Q1 FY2021 | Mar 31, 2021 | -$51.49M | – |
| Q4 FY2020 | Dec 31, 2020 | -$51.88M | – |
See a number that looks wrong?